In fact, some studies have indicated that BUB1 (Takagi et al., 2013), KIF11 (Pei et al., 2017), TTK (Sugimoto et al., 2017) and so on (Yuan et al., 2006) might be involved in tumorigenesis and become new candidate biomarkers for BC or TNBC treatment. Here, BUB1 is linked to breast cancer.